NOVO.B.DK

438.65

-3.29%↓

COLO.B.DK

601

-2.15%↓

GMAB.DK

1,373

-1.47%↓

ZEAL.DK

364.4

-3.21%↓

AMBUB.DK

96.6

-1.93%↓

NOVO.B.DK

438.65

-3.29%↓

COLO.B.DK

601

-2.15%↓

GMAB.DK

1,373

-1.47%↓

ZEAL.DK

364.4

-3.21%↓

AMBUB.DK

96.6

-1.93%↓

NOVO.B.DK

438.65

-3.29%↓

COLO.B.DK

601

-2.15%↓

GMAB.DK

1,373

-1.47%↓

ZEAL.DK

364.4

-3.21%↓

AMBUB.DK

96.6

-1.93%↓

NOVO.B.DK

438.65

-3.29%↓

COLO.B.DK

601

-2.15%↓

GMAB.DK

1,373

-1.47%↓

ZEAL.DK

364.4

-3.21%↓

AMBUB.DK

96.6

-1.93%↓

NOVO.B.DK

438.65

-3.29%↓

COLO.B.DK

601

-2.15%↓

GMAB.DK

1,373

-1.47%↓

ZEAL.DK

364.4

-3.21%↓

AMBUB.DK

96.6

-1.93%↓

Search

H Lundbeck A-S

Closed

34.74 1.34

Overview

Share price change

24h

Current

Min

34.72

Max

35.24

Key metrics

By Trading Economics

Income

562M

1.2B

Sales

694M

6.2B

P/E

Sector Avg

10.602

39.564

EPS

1.53

Dividend yield

2.61

Profit margin

18.476

Employees

5,700

EBITDA

811M

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.61%

2.40%

Market Stats

By TradingEconomics

Market Cap

-3B

34B

Previous open

33.4

Previous close

34.74

H Lundbeck A-S Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lip 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

FCC Approves U.S. Cellular Sale to T-Mobile

11 lip 2025, 17:28 UTC

Major Market Movers

SharpLink Gaming Gains on Ethereum Purchase

11 lip 2025, 16:57 UTC

Earnings

BASF Cuts Outlook on Global Economy Uncertainty

11 lip 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 lip 2025, 19:46 UTC

Acquisitions, Mergers, Takeovers

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 lip 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 lip 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 lip 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 lip 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 lip 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 lip 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11 lip 2025, 16:42 UTC

Earnings

BASF Cuts Outlook on Global Economic Uncertainty

11 lip 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 lip 2025, 16:05 UTC

Earnings

BASF Will Publish Half-Year Results on July 30

11 lip 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11 lip 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 lip 2025, 16:03 UTC

Earnings

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 lip 2025, 16:02 UTC

Earnings

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 lip 2025, 16:01 UTC

Earnings

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 lip 2025, 16:00 UTC

Earnings

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 lip 2025, 15:59 UTC

Earnings

BASF Cuts 2025 Earnings View

11 lip 2025, 15:58 UTC

Earnings

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 lip 2025, 15:57 UTC

Earnings

BASF 2Q EBIT Before Special Items EUR810M

11 lip 2025, 15:54 UTC

Earnings

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 lip 2025, 15:54 UTC

Earnings

BASF 2Q Sales Fell 2.1% on Year

11 lip 2025, 15:53 UTC

Earnings

BASF 2Q Sales EUR15.77B

11 lip 2025, 15:52 UTC

Earnings

BASF: This Was in Line With Consensus Estimates

11 lip 2025, 15:52 UTC

Earnings

BASF 2Q Ebitda Before Special Items EUR1.77B

11 lip 2025, 15:49 UTC

Earnings

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 lip 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Peer Comparison

Price change

H Lundbeck A-S Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.